Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Tumor budding is an independent prognostic factor in colorectal cancer (CRC) and has recently been well-defined by the International Tumour Budding Consensus Conference (ITBCC).
The aim of the present study was to use the ITBCC budding evaluation method to examine the relationship between tumor budding, tumor factors, tumor microenvironment, and survival in patients with primary operable CRC.
Hematoxylin and eosin-stained slides of 952 CRC patients diagnosed between 1997 and 2007 were evaluated for tumor budding according to the ITBCC criteria. The tumor microenvironment was evaluated using tumor stroma percentage (TSP) and Klintrup–Makinen (KM) grade to assess the tumor inflammatory cell infiltrate.
High budding (n = 268, 28%) was significantly associated with TNM stage (p < 0.001), competent mismatch repair (MMR; p < 0.05), venous invasion (p < 0.001), weak KM grade (p < 0.001), high TSP (p < 0.001), and reduced cancer-specific survival (CSS) (hazard ratio 8.68, 95% confidence interval 6.30–11.97; p < 0.001). Tumor budding effectively stratifies CSS stage T1 through to T4 (all p < 0.05) independent of associated factors.
Tumor budding effectively stratifies patients’ survival in primary operable CRC independent of other phenotypic features. In particular, the combination of T stage and budding should form the basis of a new staging system for primary operable CRC.
Brown IS, Bettington ML, Bettington A, Miller G, Rosty C. Adverse histological features in malignant colorectal polyps: a contemporary series of 239 cases. J Clin Pathol. 2016;69:292–9. CrossRef
Dawson H, Koelzer VH, Karamitopoulou E, et al. The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology. 2014;64:577–84. CrossRef
Klintrup K, Mäkinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur. J. Cancer. 2005;41:2645–54. CrossRef
Loughrey M, Quirke P, Shepherd NA. Standards and datasets for reporting cancers. Dataset for histopathological reporting of colorectal cancer. Sep 2018. https://www.rcpath.org/uploads/assets/uploaded/0d5e22ce-be66-474c-ba3097adae84121d. Assessed 23 Feb 2019.
Lugli A, Karamitopoulou E, Panayiotides I, et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour ‘approach to tumour host interaction in colorectal cancer. Br J Cancer. 2009;101:1382. CrossRef
Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299. CrossRef
Mesker WE, Junggeburt J, Szuhai K, et al. The carcinoma–stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Anal. Cell. Pathol. 2007;29:387–98.
Park J, Richards C, McMillan D, Horgan P, Roxburgh C. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann. Oncol. 2014;25:644–51. CrossRef
Park JH, McMillan DC, Powell AG, et al. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer. Clin. Cancer Res. 2015;21:882–8. CrossRef
Park JH, Powell AG, Roxburgh CS, Horgan PG, McMillan DC, Edwards J. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer. 2016;114:562. CrossRef
Patel M, McSorley ST, Park JH, et al. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. Br J Cancer. 2018;118:705. CrossRef
Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology. 2005;47:17–24. CrossRef
Roxburgh CS, McMillan DC, Anderson JH, McKee RF, Horgan PG, Foulis AK. Elastica staining for venous invasion results in superior prediction of cancer-specific survival in colorectal cancer. Ann. Surg. 2010;252:989–97. CrossRef
Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer. 2009;45:2138–45. CrossRef
Rubio CA. Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report. Anticancer Res. 2008;28:2417–20. PubMed
Ueno H, Jones AM, Wilkinson KH, Jass J, Talbot I. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 2004;53:581–6. CrossRef
Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94. CrossRef
Ueno H, Murphy J, Jass J, Mochizuki H, Talbot I. Tumourbudding’as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 2002;40:127–32. CrossRef
van Wyk HC, Park JH, Edwards J, Horgan PG, McMillan DC, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer. British J Cancer. 2016;115:156. CrossRef
Wang H-S, Liang W-Y, Lin T-C, et al. Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum. 2005;48:1182–92. CrossRef
- The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer
PhD Hester C. van Wyk
PhD Antonia Roseweir
MBChB Peter Alexander
PhD James H. Park
PhD Paul G. Horgan
PhD Donald C. McMillan
PhD Joanne Edwards
- Springer International Publishing
Annals of Surgical Oncology
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II